A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
Clinical trial NCT07719023 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07719023
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-31
- Primary completion
- 2028-09-30
- Enrollment
- 263
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.